Polpharma Biologics

Executive Summary

Polpharma Biologics, a private Dutch biosimilars company founded in 2012, has undergone a strategic demerger into two independent entities. The CDMO operations have been transferred to Rezon Bio, while the remaining entity focuses on developing and commercializing biosimilar products. Despite limited public information, the company is recognized as a key player in the European biosimilars market, leveraging its parent company Polpharma's extensive pharmaceutical network. The demerger aims to sharpen strategic focus and unlock value in both the CDMO and biosimilar development segments. Polpharma Biologics continues to advance its pipeline of biosimilar candidates targeting major therapeutic areas such as oncology, immunology, and inflammatory diseases. The company's ability to navigate complex regulatory pathways and establish partnerships will be crucial for future growth and competitiveness in the rapidly evolving biosimilars landscape. With the global biosimilars market expected to expand significantly, Polpharma Biologics is well-positioned to capture market share through its differentiated product portfolio and manufacturing expertise.

Upcoming Catalysts (preview)

• Q3 2026Regulatory submission for lead biosimilar candidate (e.g., adalimumab or infliximab biosimilar)70% success
• Q4 2026Partnership or licensing agreement for commercialization in key markets60% success
• Q1 2027Initiation of Phase III trial for next-generation biosimilar50% success